lipid: Long-Term Intervention with Pravastatin in Ischemic Disease
principal researchers
John Simes (NHMRC Clinical Trials Centre, University of Sydney)
Andrew Tonkin (Department of Epidemiology and Preventive Medicine, Monash University)
data custodian
NHMRC Clinical Trials Centre, University of Sydney
funding
Bristol-Myers Squibb; National Health and Medical Research Council
key publications
- Design paper: Am J Cardiol 1995; 76: 474-479
- Main results: N Engl J Med 1998; 339: 1349-57
- Psychological well-being: Arch Intern Med 2000; 160(20); 3144-52
- Effects on Ffacture: Lancet 2001; 357(9255): 509-12
- Effects by age: Ann Intern Med 2001; 134(10): 931-40
- Non-haemorrhagic stroke: J Hypertens 2002; 20 (12): 2513-7
- 2-year follow-up and safety: Lancet 2002; 359(9315): 1379-87
- Subgroup women: Am Heart J 2003; 145 (4): 643-51
- Diabetes: Diabetes Care 2003; 26(10): 2713-21
- Depression and risk: Eur Heart J 2003; 24 (22): 2027-37
- Low LDL and low HDL subgroup: Eur Heart J 2004; 25 (9): 771-7
- Diet and risk: Am J Clin Nutr 2005; 81 (6): 1322-9
- White cell count as a predictor of risk: Circulation 2005; 111 (14): 1756-62
- Cost-effectiveness of treatment in older subgroup: Am Heart J 2006; 151 (6): 1305-12
- BNP as predictor of risk: Eur Heart J 2008; 29 (7): 923-31
- Lp(a) as predictor of risk: Arterioscler Thromb Vasc Biol 2013; 33 (12): 2902–8
- Lp-PLA2 as predictor of risk: J Am Heart Assoc 2013; 2: e000360
- MR-pro-ADM as predictor of risk: Int J Cardiol 2014; 172 (2): 411–8
- Troponin I as predictor of risk: J Am Coll Cardiol 2014; 63 (4): 345–54
- Biomarkers to predict risk: Int J Cardiol 2015; 201: 499–507